The Canadian Intellectual Property Office intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine
STOCKHOLM, Jan. 24, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, 24thJanuary 2022, that the Canadian Intellectual Property Office ("CIPO") has issued a "Notice of Allowance", which means that it intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine.
- STOCKHOLM, Jan. 24, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, 24thJanuary 2022, that the Canadian Intellectual Property Office ("CIPO") has issued a "Notice of Allowance", which means that it intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine.
- The Canadian patent will provide RhoVac's onilcamotide vaccine with broad protection in a key market and significantly strengthens the company's patent portfolio.
- The Canadian Intellectual Property Office ("CIPO") has communicated its intention to grant RhoVac's Patent Application No.
- The patent covers RhoVac's onilcamotide cancer vaccine, possible variants of the vaccine and the use of such vaccines in the treatment or prevention of metastatic cancer where RhoC is expressed.